Aurinia Pharmaceuticals AUPH Insider Ownership

NASDAQ AUPH

$16.74 +0.25 (+1.52%)

At close: Oct 20, 2026 · 4:00 PM EDT

Insider Holdings by Owner

18.71Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

12.99%

▼-0.368% pp QoQ

Shares Held by Insiders

17.26Mn

filed for Sep 2026

▼-2.75% QoQ

Shares Outstanding

132.91Mn

132,907,000 shares

Direct Holdings

4.22Mn

Indirect: 13.04Mn

Net Shares Traded (QoQ)

-488.89K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past 12 months, Aurinia Pharmaceuticals insiders bought $25.14 million of stock on the open market (1.71Mn shares) and sold $546,373 (32.91K shares).

Among Aurinia Pharmaceuticals' insiders, Kevin Tang (Chief Executive Officer) was the largest open-market buyer over the past 12 months, purchasing $25.14 million of stock (1.71Mn shares), most recently on June 2, 2026.
On the selling side, Stephen P. Robertson (Chief Legal Officer) sold the most Aurinia Pharmaceuticals stock on the open market over the past 12 months, $546,373 (32.91K shares), most recently on September 10, 2026.
Apart from open-market trades, AUPH insiders received 960.3K shares in stock awards and gave up 680.7K shares to cover taxes or exercise prices in the past 12 months.
According to Business Quant data, insiders at Aurinia Pharmaceuticals reported 17.26Mn shares in total in their latest Form 4 filings, down 2.75% from 17.75Mn shares at the end of Q2 2026 and up 7.80% from 16.01Mn shares at the end of Q3 2025.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 75.57% (13.04Mn shares) of Aurinia Pharmaceuticals' insider total, with the other 24.43% (4.22Mn shares) held directly.
Per Business Quant, 13 insiders of AUPH hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
Aurinia Pharmaceuticals' three largest insider shareholders, based on their latest Form 4 filings, are Kevin Tang (Chief Executive Officer, 13.04Mn shares), Peter Greenleaf (Chief Executive Officer, 1.84Mn shares) and Matthew Maxwell Donley (Chief Operating Officer, 680.3K shares).
Of the shares held by AUPH insiders, 75.57% belong to Kevin Tang.
Institutional holders reported 58.68% of Aurinia Pharmaceuticals' outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 12.99%, and other investors, including the public, hold the remaining 28.33%.
In the past year, 12 insiders of Aurinia Pharmaceuticals submitted 28 Form 4 filings reporting trades, awards or other transactions.
The insider holdings and trades above for Aurinia Pharmaceuticals reflect Form 4 filings through September 11, 2026.

Form 4 Holdings

Insiders Holding AUPH

Insiders 24

Shares held 18.71Mn

Of outstanding 14.08%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Kevin Tang	Chief Executive Officer	0	13,044,106	13,044,106	69.7%	02 Jun, 2026
2	Peter Greenleaf	Chief Executive Officer	1,840,379	0	1,840,379	9.8%	03 Mar, 2026
3	Matthew Maxwell Donley	Chief Operating Officer	680,299	0	680,299	3.6%	03 Mar, 2026
4	Stephen P. Robertson	Chief Legal Officer	588,848	0	588,848	3.1%	11 Sep, 2026
5	Joseph M Miller	Chief Financial Officer	576,421	0	576,421	3.1%	03 Mar, 2026
6	Scott Michael Habig	Chief Commercial Officer	456,338	0	456,338	2.4%	07 Aug, 2024
7	Volker Knappertz	Evp, Research And Development	319,128	0	319,128	1.7%	29 Feb, 2024
8	Michael Robert Martin	Chief Business Officer	259,162	0	259,162	1.4%	06 Mar, 2023
9	Greg Keenan	Svp, Chief Medical Officer	154,449	0	154,449	0.8%	10 Mar, 2026
10	Ryan Cole	Chief Operating Officer	116,144	0	116,144	0.6%	20 May, 2026
11	Michael S Hearne	Chief Financial Officer	116,144	0	116,144	0.6%	20 May, 2026
12	David R.W. Jayne	Director	100,863	0	100,863	0.5%	25 Nov, 2024
13	Neil Solomons	Chief Medical Officer	90,953	0	90,953	0.5%	04 Mar, 2022
14	George M Jr Milne	Director	78,733	0	78,733	0.4%	23 May, 2023
15	Robert Bindert Huizinga	Evp Of Research	69,379	0	69,379	0.4%	04 Mar, 2022
16	Jill Leversage	Director	37,971	0	37,971	0.2%	25 Nov, 2024
17	Karen L. Smith	Director	37,479	0	37,479	0.2%	25 Nov, 2024
18	Jeffrey Allen Bailey	Director	36,131	0	36,131	0.2%	24 Nov, 2025
19	Daniel Billen	Director	28,141	0	28,141	0.2%	22 May, 2024
20	R. Hector Mackay-Dunn	Director	18,595	0	18,595	0.1%	22 May, 2024
21	Brinda Balakrishnan	Director	17,523	0	17,523	0.1%	22 May, 2024
22	Craig A Johnson	Director	14,592	0	14,592	0.1%	24 Nov, 2025
23	Massimilano Colao	Chief Commercial Officer	13,495	0	13,495	0.1%	04 Mar, 2022
24	Joseph P Hagan	Director	11,961	0	11,961	0.1%	23 May, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

341 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
10 Sep, 2026	Stephen P. Robertson	Chief Legal Officer	Disposed S	11,939	$15.95	$190.43K	588,848	Direct
21 Aug, 2026	Stephen P. Robertson	Chief Legal Officer	Disposed S	20,975	$16.97	$355.95K	600,787	Direct
04 Jun, 2026	Jeffrey Allen Bailey	Director	Acquired A	23,931	$0.00	$0	23,931	Direct
04 Jun, 2026	Tina Susan Nova	Director	Acquired A	23,931	$0.00	$0	23,931	Direct
04 Jun, 2026	Craig A Johnson	Director	Acquired A	23,931	$0.00	$0	23,931	Direct
04 Jun, 2026	Kathleen Goetz	Director	Acquired A	23,931	$0.00	$0	23,931	Direct
29 May, 2026	Kevin Tang	Chief Executive Officer	Acquired P	2,299	$15.35	$35.29K	12,231,799	Indirect
29 May, 2026	Kevin Tang	Chief Executive Officer	Acquired P	262,682	$15.31	$4.02Mn	12,494,481	Indirect
01 Jun, 2026	Kevin Tang	Chief Executive Officer	Acquired P	343,521	$15.28	$5.25Mn	12,838,002	Indirect
01 Jun, 2026	Kevin Tang	Chief Executive Officer	Acquired P	99	$15.34	$1.52K	12,838,101	Indirect
02 Jun, 2026	Kevin Tang	Chief Executive Officer	Acquired P	206,005	$15.28	$3.15Mn	13,044,106	Indirect
02 Jun, 2026	Kevin Tang	Chief Executive Officer	Acquired J	10,000	$1.65	$16.50K	10,000	Indirect
18 May, 2026	Stephen P. Robertson	Chief Legal Officer	Acquired A	115,541	$0.00	$0	621,402	Direct
18 May, 2026	Michael S Hearne	Chief Financial Officer	Acquired A	116,144	$0.00	$0	116,144	Direct
18 May, 2026	Ryan Cole	Chief Operating Officer	Acquired A	116,144	$0.00	$0	116,144	Direct
18 May, 2026	Ryan Cole	Chief Operating Officer	Acquired A	70,230	$0.00	$0	70,230	Direct
18 May, 2026	Michael S Hearne	Chief Financial Officer	Acquired A	70,230	$0.00	$0	70,230	Direct
06 Mar, 2026	Greg Keenan	Svp, Chief Medical Officer	Disposed F	8,069	$14.32	$115.55K	154,449	Direct
27 Feb, 2026	Kevin Tang	Director	Acquired P	300,000	$13.90	$4.17Mn	11,629,500	Indirect
27 Feb, 2026	Peter Greenleaf	Chief Executive Officer	Acquired A	196,403	$0.00	$0	1,941,269	Direct

Showing 1 to 20 of 341 transactions